These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1006 related articles for article (PubMed ID: 31714156)

  • 1. NK cell-based therapeutics for lung cancer.
    Pockley AG; Vaupel P; Multhoff G
    Expert Opin Biol Ther; 2020 Jan; 20(1):23-33. PubMed ID: 31714156
    [No Abstract]   [Full Text] [Related]  

  • 2. Full-length recombinant antibodies from
    Rashid MH
    MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
    Seledtsov VI; Goncharov AG; Seledtsova GV
    Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic gene modified cell based cancer vaccines.
    Kozłowska A; Mackiewicz J; Mackiewicz A
    Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.
    Xue Y; Gao S; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X; Wu R
    Expert Opin Drug Deliv; 2021 Feb; 18(2):187-203. PubMed ID: 32954856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer cell biology: an update and future directions.
    Campbell KS; Hasegawa J
    J Allergy Clin Immunol; 2013 Sep; 132(3):536-544. PubMed ID: 23906377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune evasion by cancer stem cells.
    Tsuchiya H; Shiota G
    Regen Ther; 2021 Jun; 17():20-33. PubMed ID: 33778133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological drug and drug delivery-mediated immunotherapy.
    Xiao Q; Li X; Li Y; Wu Z; Xu C; Chen Z; He W
    Acta Pharm Sin B; 2021 Apr; 11(4):941-960. PubMed ID: 33996408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
    Braster R; O'Toole T; van Egmond M
    Methods; 2014 Jan; 65(1):28-37. PubMed ID: 23811299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monocytes and the 38kDa-antigen of mycobacterium tuberculosis modulate natural killer cell activity and their cytolysis directed against ovarian cancer cell lines.
    Gottschalk N; Lang S; Kimmig R; Singh M; Brandau S
    BMC Cancer; 2012 Oct; 12():451. PubMed ID: 23036052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors.
    Wingert S; Reusch U; Knackmuss S; Kluge M; Damrat M; Pahl J; Schniegler-Mattox U; Mueller T; Fucek I; Ellwanger K; Tesar M; Haneke T; Koch J; Treder M; Fischer W; Rajkovic E
    MAbs; 2021; 13(1):1950264. PubMed ID: 34325617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
    Kim N; Kim HS
    Front Immunol; 2018; 9():2041. PubMed ID: 30250471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging targets in cancer immunotherapy.
    Burugu S; Dancsok AR; Nielsen TO
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):39-52. PubMed ID: 28987965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors.
    Le Maux Chansac B; Moretta A; Vergnon I; Opolon P; Lécluse Y; Grunenwald D; Kubin M; Soria JC; Chouaib S; Mami-Chouaib F
    J Immunol; 2005 Nov; 175(9):5790-8. PubMed ID: 16237071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of PD-1 Blockade in Cancer Immunotherapy.
    Wu X; Gu Z; Chen Y; Chen B; Chen W; Weng L; Liu X
    Comput Struct Biotechnol J; 2019; 17():661-674. PubMed ID: 31205619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment.
    Yang M; Li J; Gu P; Fan X
    Bioact Mater; 2021 Jul; 6(7):1973-1987. PubMed ID: 33426371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation.
    Eitler J; Rackwitz W; Wotschel N; Gudipati V; Murali Shankar N; Sidorenkova A; Huppa JB; Ortiz-Montero P; Opitz C; Künzel SR; Michen S; Temme A; Loureiro LR; Feldmann A; Bachmann M; Boissel L; Klingemann H; Wels WS; Tonn T
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38417916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leveraging NKG2D Ligands in Immuno-Oncology.
    Fuertes MB; Domaica CI; Zwirner NW
    Front Immunol; 2021; 12():713158. PubMed ID: 34394116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
    Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
    IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF inhibitor resistance of melanoma cells triggers increased susceptibility to natural killer cell-mediated lysis.
    Frazao A; Rethacker L; Jeudy G; Colombo M; Pasmant E; Avril MF; Toubert A; Moins-Teisserenc H; Roelens M; Dalac S; Maubec E; Caignard A
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32912923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.